MEDICATION DEVELOPMENT FOR COCAINE ABUSERS

针对可卡因滥用者的药物开发

• 批准号: 8357378
• 负责人: MICHAEL J KUHAR
• 金额: $ 3.29万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357378
• 关键词: Cocaine; Development; Funding; Grant; Human; Laboratories; National Center for Research Resources; Pharmaceutical Preparations; Phase I Clinical Trials; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Source; Testing; Toxic effect; United States National Institutes of Health; Writing; cost

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. RTI-336, a compound first tested and characterized in our laboratories, has been approved for Phase I clinical trials in humans. As of this writing, no toxic effects were found that preclude further study, and additional studies are planned in humans. RTI-336 would be a new medication for cocaine addicts.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 RTI-336是一种首先在我们的实验室进行测试和表征的化合物，已被批准用于人类第一阶段临床试验。 在撰写这篇文章时，还没有发现排除进一步研究的毒性影响，还计划在人体上进行更多研究。 RTI-336将成为一种治疗可卡因成瘾者的新药。